HumanZyme® Launches New Human Cell-Expressed LIF (Leukemia Inhibitory Factor) For Stem Cell Research and Regenerative Medicine Applications
Chicago, IL (PRWEB) August 17, 2016 -- HumanZyme Inc., a leading supplier of novel human proteins and growth factors expressed in human cells enabling stem cell research and regenerative therapy applications, today announced the launch of a new HumanKine® authentic recombinant human protein, LIF (Leukemia Inhibitory Factor). Human-cell expressed LIF has native human glycosylation, important since LIF is a highly glycosylated protein, also ensuring the best possible stability and activity in cell culture. The new LIF introduction expands the HumanKine product line of high-quality, native human proteins expressed in human cells available from HumanZyme.
“This new LIF HumanKine protein is an important addition to our product line of authentic recombinant human cytokines and growth factors for stem cell research. We are working hard to expand our offerings to include a complete set of native human recombinant proteins used for stem cell expansion, differentiation and maintenance. LIF is priced competitively, is animal-derived product free and available in bulk,” said Scott Coleridge, CEO at HumanZyme.
LIF is used to promote long-term maintenance of embryonic stem cells by suppressing spontaneous differentiation when added to culture medium, and is an important tool for stem cell researchers. Recombinant HumanKine LIF expressed in HEK293 cells provides native human post-translational processing including glycosylation, disulfide links, subunit assembly and folding for native activity and stability.
For more information, see our LIF product page.
About HumanZyme, Inc.
HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide—from academic and government research institutions to biotechnology and pharmaceutical companies.
Brenda Wiggins, HumanZyme, Inc., http://www.humanzyme.com, +1 312.738.0127, [email protected]
Share this article